U.S. House Speaker Touts Benefits Of CBD And Industrial Hemp

The top Republican in the U.S. House has issued a surprise endorsement of a key marijuana ingredient’s medical benefits, as well as the uses of industrial hemp.

“It has proven to work,” Republican House Speaker Paul Ryan said of cannabidiol (CBD) on Oct. 30, 2018, specifying that it “helps reduce seizures.”

“We do this in Wisconsin,” he said, referring to his home state’s limited CBD law. “That that oil, I think works well.”

The speaker, who is not running for re-election and is retiring from Congress early next year, shared that his own mother-in-law used a synthetic form of cannabinoids, presumably the tetrahydrocannabinol (THC) pill Marinol, while dying from melanoma and ovarian cancer.

“That’s off the record,” he said jokingly, referencing TV cameras at the well-attended Kentucky rally where he was appearing in support of Republican Rep. Andy Barr, who is locked in a tight re-election race.

Ryan, responding to a medical marijuana question from a woman whose husband died, also proactively took the opportunity to speak up in support of industrial hemp.

“And by the way, there’s a lot of industrial uses for hemp that I understand from talking to Mitch McConnell is a big deal to Kentucky agriculture,” he said. “And we’re all in favor of that as well.”

Ryan’s endorsement for hemp comes at a key time. Congressional leaders are currently negotiating differences in the House and Senate versions of the Farm Bill. The Senate proposal contains language championed by McConnell, the GOP majority leader, that would legalize hemp. The House bill has no such provisions.

If the top Republican in either chamber is now vocally in support of ending the prohibition on marijuana’s non-intoxicating cousin, it seems more and more likely that the House will accept the Senate’s hemp language.

That said, don’t count the outgoing speaker as a die-hard marijuana supporter, even when it comes to medical uses.

“There’s no THC in that oil,” he said, even though most CBD preparations do have small amounts of the intoxicating cannabis compound. “That is not medical marijuana.”

In response to the medical marijuana question, Ryan also touted passage this year of the Right to Try Act — which appears to allow certain seriously ill people to use marijuana and other currently illegal drugs such as psilocybin, or “magic mushrooms,” and MDMA, popularly called ecstasy, though he did not mention those implications directly.

This article has been republished from Marijuana Moment under a content syndication agreement. Read the original article here.

Original Article Source: https://www.marijuana.com/news/2018/10/u-s-house-speaker-touts-benefits-of-cbd-and-industrial-hemp/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Mormon Church Faces Potential Lawsuit Over Medical Marijuana Opposition

Political committees concerned with marijuana law reform in four states have waged an information war over the past year, first to qualify cannabis initiatives for the ballot, and then to support or oppose those measures in the lead-up to last week’s midterm elections. In total, over $12.9 million in cash and in-kind services was spent attempting to convince voters about these marijuana ballot measures. Now that voters have had their say, Marijuana Moment decided to calculate how much each “yes” and “no” vote cost the committees on either side of the debate. Our calculations are based on dollars raised and disclosed before the election, since final totals of actual expenditures won’t be available until December or January reports required in the states that voted on cannabis. Michigan In Michigan, where voters approved marijuana legalization , our calculations show that the two anti-legalization committees spent about $1.28 per “no” vote, as they raised $2.37 million for ...

Norma Pence

Search This Blog